At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 115 enrolled
Drug / intervention
Bemcentinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
In Brief
A Phase 2 clinical trial evaluating Bemcentinib and SoC for COVID-19. Completed, enrolled 115 participants across 12 sites in 2 countries.
Detailed Summary
The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesIndia, South Africa
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedMay 2021
Primary CompletionMay 2021
TodayJul 2026
First PostedMay 18, 2021
Enrollment StartOct 20, 2020
Primary CompletionMay 25, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.1 years ago
Interventions
Bemcentinibdrug
Bemcentinib capsules will be administered orally.
SoCother
The SoC will be administered based on local guidelines.